# Risk Matrix: In-House Production Deployment

## Risk Assessment Summary

**Total Risks Identified:** 9
**Critical (High Severity):** 3
**Medium Severity:** 4
**Low Severity:** 2

---

## Risk Matrix Table

| Risk ID | Risk | Impact | Likelihood | Severity | Mitigation Priority |
|---------|------|--------|------------|----------|-------------------|
| **R1** | Patient Data Privacy Breach (HIPAA/GDPR) | **Critical** | Medium | **ðŸ”´ HIGH** | **Immediate** |
| **R2** | Cost Overruns from Real Data Processing | **High** | High | **ðŸ”´ HIGH** | **Immediate** |
| **R3** | Mocked Servers Deployed to Production | **Critical** | Medium | **ðŸ”´ HIGH** | **Immediate** |
| **R4** | External API Failures (TCGA, HuggingFace) | **Medium** | High | **ðŸŸ¡ MEDIUM** | High |
| **R5** | Poor Data Quality / File Format Issues | **Medium** | Medium | **ðŸŸ¡ MEDIUM** | High |
| **R6** | Infrastructure Capacity Limitations | **Medium** | Medium | **ðŸŸ¡ MEDIUM** | Medium |
| **R7** | Incorrect Clinical Recommendations | **High** | Low | **ðŸŸ¡ MEDIUM** | High |
| **R8** | Regulatory/Clinical Validation Gaps | **Medium** | Low | **ðŸŸ¢ LOW** | Medium |
| **R9** | User Adoption Resistance | **Low** | Medium | **ðŸŸ¢ LOW** | Low |

---

## Detailed Risk Analysis

### ðŸ”´ CRITICAL SEVERITY RISKS

---

### **R1: Patient Data Privacy Breach (HIPAA/GDPR)**

**Impact:** Critical
**Likelihood:** Medium (25-50% without proper controls)
**Severity Score:** ðŸ”´ **HIGH (9/10)**

**Description:**
Real patient genomic, clinical, and imaging data processed by MCP servers could be exposed through:
- Insufficient access controls on data directories
- Logs containing PHI/PII written to disk
- Claude API calls potentially exposing patient identifiers
- MCP server responses cached insecurely

**Potential Consequences:**
- HIPAA violations: $100-$50,000 per violation, up to $1.5M annually
- GDPR violations: Up to â‚¬20M or 4% of global revenue
- Loss of institutional trust and patient consent
- Legal liability and lawsuits
- Reputation damage

**Mitigation Strategies:**

1. **De-identification Before Processing (CRITICAL)**
   - Remove all 18 HIPAA identifiers from data files before MCP processing
   - Use pseudonymization with secure key management
   - Never pass patient names, MRNs, dates of birth to Claude API

2. **Data Access Controls**
   - Restrict `MULTIOMICS_DATA_DIR`, `SPATIAL_DATA_DIR` to authorized users only
   - Use filesystem permissions (700/750) on all data directories
   - Implement role-based access control (RBAC)

3. **Secure Logging**
   - Configure all MCP servers to disable verbose logging in production
   - Redact PHI from log files automatically
   - Use secure log aggregation (e.g., HIPAA-compliant logging service)

4. **API Security**
   - Review Claude Desktop's data retention policy
   - Consider self-hosted Claude API deployment for maximum control
   - Encrypt all data in transit and at rest

5. **Compliance Audit**
   - Conduct HIPAA Security Risk Assessment before go-live
   - Implement Business Associate Agreement (BAA) with Anthropic if applicable
   - Regular penetration testing and security audits

**Risk Owner:** Chief Information Security Officer (CISO) / Compliance Team

**Timeline:** Must be resolved BEFORE any real patient data processing

---

### **R2: Cost Overruns from Real Data Processing**

**Impact:** High
**Likelihood:** High (50-75% if not monitored)
**Severity Score:** ðŸ”´ **HIGH (8/10)**

**Description:**
Actual computational costs may significantly exceed estimates from COST_ANALYSIS.md:
- Spatial transcriptomics alignment taking 2-3x longer than estimated
- GPU costs for DeepCell running 24/7 instead of on-demand
- API costs for HuggingFace/Seqera exceeding free tiers
- Storage costs for intermediate files (BAMs, segmentation masks)

**Potential Consequences:**
- Budget exhaustion mid-project
- Need to halt patient processing
- Emergency funding requests
- Project perceived as financially unsustainable

**Estimated Cost Range:**
- **Conservative estimate:** $15-45 per patient (from COST_ANALYSIS.md)
- **Realistic with overruns:** $25-75 per patient (67-100% increase)
- **Worst case:** $50-150 per patient (233-400% increase)

**Cost Breakdown by Component:**

| Component | Estimated | Realistic | Worst Case |
|-----------|-----------|-----------|------------|
| Spatial alignment (STAR) | $5-10 | $10-20 | $20-40 |
| DeepCell segmentation | $2-3 | $5-8 | $10-15 |
| Multi-omics processing | $2-4 | $3-6 | $5-10 |
| HuggingFace API | $0-2 | $2-5 | $5-10 |
| Storage & transfer | $1-3 | $3-8 | $5-15 |
| Claude tokens | $0.50 | $0.50-1 | $1-2 |
| **TOTAL** | **$15-45** | **$25-75** | **$50-150** |

**Mitigation Strategies:**

1. **Pilot with Cost Monitoring**
   - Process 5-10 patients first with detailed cost tracking
   - Use cloud cost monitoring tools (AWS Cost Explorer, GCP Billing)
   - Set up budget alerts ($500, $1000, $2500 thresholds)

2. **Optimization Before Scale**
   - Profile STAR alignment to find bottlenecks
   - Test spot instances vs on-demand for 40-60% savings
   - Implement caching for reference genomes and model weights
   - Use pre-computed results when possible

3. **Tiered Processing**
   - Offer "Basic" analysis (skip DeepCell, spatial) for $5-10
   - "Standard" analysis (current scope) for $15-45
   - "Comprehensive" (add new features) for $50-100
   - Let users choose based on budget

4. **Cost Caps Per Patient**
   - Implement hard limits: e.g., $100 max per patient analysis
   - Auto-stop pipelines exceeding threshold
   - Alert before expensive steps (spatial alignment)

5. **Resource Optimization**
   - Use Nextflow resource directives to limit CPU/memory
   - Implement job queuing to use resources efficiently
   - Consider hybrid: local compute for cheap tasks, cloud for GPU

**Risk Owner:** Finance/Operations Manager + Technical Lead

**Timeline:** Pilot testing within first 2 weeks of deployment

---

### **R3: Mocked Servers Deployed to Production**

**Impact:** Critical
**Likelihood:** Medium (25-50% without proper testing)
**Severity Score:** ðŸ”´ **HIGH (9/10)**

**Description:**
Accidentally running mocked servers (DRY_RUN=true) in production environment, or deploying servers with 0% real implementation:
- mcp-tcga, mcp-deepcell, mcp-huggingface, mcp-seqera currently 100% mocked
- mcp-spatialtools only 40% real implementation
- Returning synthetic results instead of actual analysis

**Potential Consequences:**
- **CATASTROPHIC:** Incorrect clinical recommendations based on fake data
- Patient harm if treatment decisions made on synthetic results
- Loss of clinical credibility
- Malpractice liability
- Immediate project shutdown

**Current Server Status:**

| Server | Real Implementation | Risk if Deployed As-Is |
|--------|-------------------|------------------------|
| mcp-multiomics | 85% real | ðŸŸ¢ Low - Production ready |
| mcp-fgbio | 65% real | ðŸŸ¢ Low - Production ready |
| mcp-spatialtools | 40% real | ðŸŸ¡ Medium - Partial functionality |
| mcp-openimagedata | 30% real | ðŸ”´ High - Mostly mocked |
| mcp-tcga | 0% real | ðŸ”´ **CRITICAL** - Fully mocked |
| mcp-deepcell | 0% real | ðŸ”´ **CRITICAL** - Fully mocked |
| mcp-huggingface | 0% real | ðŸ”´ **CRITICAL** - Fully mocked |
| mcp-seqera | 0% real | ðŸ”´ **CRITICAL** - Fully mocked |
| mcp-mockepic | 0% real (intentional) | ðŸŸ¢ Low - Mock EHR by design |

**Mitigation Strategies:**

1. **Production Readiness Checklist (MANDATORY)**
   - Create checklist for each server before production use
   - Require sign-off from 2 technical reviewers
   - Automated tests that verify DRY_RUN=false behavior
   - Flag any server returning synthetic/mocked data

2. **Environment-Based Configuration**
   ```json
   // production.claude_desktop_config.json
   {
     "multiomics": {
       "env": {
         "MULTIOMICS_DRY_RUN": "false",  // REQUIRED
         "ENVIRONMENT": "PRODUCTION"      // Add environment flag
       }
     }
   }
   ```
   - Require explicit ENVIRONMENT=PRODUCTION flag
   - Add startup checks that verify configuration
   - Log warnings if DRY_RUN detected in production

3. **Graduated Deployment**
   - **Phase 1:** Deploy ONLY mcp-multiomics + mcp-fgbio (production-ready)
   - **Phase 2:** Complete mcp-spatialtools (3-4 weeks development)
   - **Phase 3:** Add imaging/ML servers after full implementation
   - DO NOT deploy mocked servers to production

4. **Output Validation**
   - Add "SYNTHETIC DATA" watermark to all DRY_RUN responses
   - Implement output validators that detect mocked patterns
   - Require human review of all results before clinical use

5. **Automated Testing**
   ```python
   # Pre-deployment test
   def test_production_servers_not_mocked():
       for server in production_servers:
           assert server.dry_run == False
           result = server.run_test_case()
           assert "SYNTHETIC" not in result
           assert result.contains_real_computation()
   ```

**Risk Owner:** Technical Lead + QA Lead

**Timeline:** Complete before ANY production deployment

---

## ðŸŸ¡ MEDIUM SEVERITY RISKS

---

### **R4: External API Failures (TCGA, HuggingFace, Seqera)**

**Impact:** Medium
**Likelihood:** High (50-75% - APIs have downtime)
**Severity Score:** ðŸŸ¡ **MEDIUM (6/10)**

**Description:**
Dependency on external APIs introduces points of failure:
- TCGA GDC API downtime or rate limiting
- HuggingFace Inference API overloaded or quota exceeded
- Seqera Platform service interruptions
- Network connectivity issues

**Potential Consequences:**
- Analysis pipeline failures mid-run
- Incomplete results requiring re-processing
- Delays in time-sensitive clinical cases
- User frustration and lost productivity

**Mitigation Strategies:**

1. **Graceful Degradation**
   - Design workflows to continue without optional API calls
   - E.g., skip TCGA comparison if API unavailable, but complete other analysis
   - Provide partial results with clear indicators of missing data

2. **Retry Logic with Exponential Backoff**
   ```python
   max_retries = 3
   for attempt in range(max_retries):
       try:
           result = tcga_api.query(...)
           break
       except APIError:
           wait_time = 2 ** attempt  # 1s, 2s, 4s
           time.sleep(wait_time)
   ```

3. **Caching & Offline Mode**
   - Cache TCGA cohort data locally (updated weekly)
   - Download HuggingFace models for local inference
   - Reduce real-time API dependency

4. **Monitoring & Alerting**
   - Monitor API health endpoints
   - Alert when API response times > 5 seconds
   - Track API quota usage (HuggingFace free tier limits)

5. **Fallback Options**
   - Primary: HuggingFace API â†’ Fallback: Local model
   - Primary: Seqera Platform â†’ Fallback: Local Nextflow execution

**Risk Owner:** DevOps Engineer

**Timeline:** Implement before processing first 20 patients

---

### **R5: Poor Data Quality / File Format Issues**

**Impact:** Medium
**Likelihood:** Medium (25-50% - real data is messy)
**Severity Score:** ðŸŸ¡ **MEDIUM (5/10)**

**Description:**
Real patient data may not match expected formats from synthetic test data:
- FASTQ files with non-standard quality encoding
- VCF files with missing required fields
- Spatial transcriptomics with different coordinate systems
- Image files in unexpected formats (DICOM vs TIFF)

**Potential Consequences:**
- Pipeline failures requiring manual intervention
- Incorrect results from malformed input
- Need for extensive data cleaning and preprocessing
- Delays in time-to-result

**Mitigation Strategies:**

1. **Input Validation Layer**
   - Strict schema validation for all input files
   - Fail fast with clear error messages
   - Provide data quality report before processing

2. **Comprehensive Test Suite**
   - Test with real data from multiple sources before go-live
   - Include "dirty" data edge cases in test suite
   - Partner institutions: request sample files early

3. **Data Preprocessing Pipeline**
   - Standardize file formats on ingest
   - Convert DICOM â†’ TIFF, non-standard FASTQ â†’ standard
   - Document expected formats clearly

4. **User Guidance**
   - Create data preparation guide for users
   - Provide format validation tool they can run locally
   - Example: "Run this script before upload to check compatibility"

**Risk Owner:** Data Engineer + Bioinformatics Lead

**Timeline:** Test with real data from 3+ sources during pilot

---

### **R6: Infrastructure Capacity Limitations**

**Impact:** Medium
**Likelihood:** Medium (25-50%)
**Severity Score:** ðŸŸ¡ **MEDIUM (5/10)**

**Description:**
On-premise infrastructure may be insufficient for concurrent patient analyses:
- GPU contention (only 1-2 GPUs available, but 5 patients queued)
- Storage exhaustion (BAM files 50-100GB each)
- Network bandwidth limitations
- CPU/RAM bottlenecks during peak usage

**Potential Consequences:**
- Long queue times (hours to days)
- System crashes from resource exhaustion
- Need for emergency infrastructure upgrades
- Poor user experience

**Mitigation Strategies:**

1. **Capacity Planning**
   - Estimate concurrent users: e.g., 10 patients/day Ã— 4 hours each = 1.6 concurrent
   - GPU requirements: 1 GPU can handle 3-4 concurrent DeepCell jobs
   - Storage: 100GB per patient Ã— 50 patients = 5TB minimum

2. **Resource Quotas & Job Queuing**
   - Implement SLURM or similar job scheduler
   - Limit concurrent jobs per user
   - Priority queue for urgent clinical cases

3. **Hybrid Cloud Burst**
   - Run routine analyses on-premise
   - Burst to AWS/GCP for peak demand
   - Use Nextflow's cloud executor support

4. **Data Lifecycle Management**
   - Automatically archive results after 90 days
   - Delete intermediate files after analysis complete
   - Compress BAM files (60% size reduction)

**Risk Owner:** Infrastructure/DevOps Team

**Timeline:** Baseline capacity testing in first month

---

### **R7: Incorrect Clinical Recommendations**

**Impact:** High
**Likelihood:** Low (10-25% with proper validation)
**Severity Score:** ðŸŸ¡ **MEDIUM (6/10)**

**Description:**
AI-generated treatment recommendations could be incorrect due to:
- Bugs in statistical analysis (Stouffer's, upstream regulators)
- Misinterpretation of complex genomic data by LLM
- Hallucinations in Claude's synthesis
- Outdated clinical trial information

**Potential Consequences:**
- Patient harm from inappropriate treatment
- Malpractice claims
- Loss of clinician trust
- Regulatory scrutiny

**Mitigation Strategies:**

1. **Human-in-the-Loop (MANDATORY)**
   - NEVER auto-apply recommendations
   - Require board-certified oncologist review
   - Clearly label outputs as "decision support, not directive"

2. **Recommendation Validation**
   - Cross-reference against clinical guidelines (NCCN, ASCO)
   - Require citations for all treatment suggestions
   - Flag recommendations not in standard-of-care

3. **Conservative Thresholds**
   - Only suggest treatments with strong evidence (p < 0.001)
   - Require multiple concordant signals (genomic + transcriptomic)
   - Avoid suggesting off-label uses without explicit warning

4. **Audit Trail**
   - Log all data inputs and recommendations
   - Enable retrospective review if outcomes are poor
   - Track recommendation acceptance rate by clinicians

5. **Disclaimer & Labeling**
   ```
   IMPORTANT: This analysis is for RESEARCH PURPOSES ONLY.
   Not validated for clinical decision-making.
   All recommendations must be reviewed by qualified oncologist.
   ```

**Risk Owner:** Clinical Director + Chief Medical Officer

**Timeline:** Establish review process before pilot

---

## ðŸŸ¢ LOW SEVERITY RISKS

---

### **R8: Regulatory/Clinical Validation Gaps**

**Impact:** Medium
**Likelihood:** Low (10-25%)
**Severity Score:** ðŸŸ¢ **LOW (3/10)**

**Description:**
If positioned as a clinical diagnostic tool, may need FDA clearance or CLIA certification:
- FDA requires validation for "clinical decision support" software
- CLIA lab certification for diagnostic testing
- Reimbursement requires clinical validation studies

**Potential Consequences:**
- Cannot be used for clinical (billable) diagnostics
- Limited to research use only
- Delays in broad adoption
- Additional validation costs ($50K-$500K)

**Mitigation Strategies:**

1. **Research Use Only (RUO) Positioning**
   - Clearly label as research tool, not diagnostic
   - Avoid claims about clinical outcomes
   - Position as "bioinformatics assistance" not "diagnosis"

2. **Gradual Clinical Validation**
   - Publish retrospective validation study (N=50-100 patients)
   - Compare AI recommendations vs expert panel
   - Demonstrate concordance and safety

3. **Regulatory Pathway Assessment**
   - Consult with FDA regulatory expert early
   - Determine if clinical decision support exemption applies
   - Plan for future validation if clinical use desired

**Risk Owner:** Regulatory Affairs + Legal

**Timeline:** Assessment in first 6 months, not blocking for research use

---

### **R9: User Adoption Resistance**

**Impact:** Low
**Likelihood:** Medium (25-50%)
**Severity Score:** ðŸŸ¢ **LOW (3/10)**

**Description:**
Clinicians and researchers may resist using the system due to:
- Lack of trust in AI-generated recommendations
- Complexity of setup and operation
- Preference for existing manual workflows
- Concerns about liability

**Potential Consequences:**
- Low utilization despite investment
- System sits idle
- Difficult to demonstrate value
- Budget cuts for future development

**Mitigation Strategies:**

1. **Stakeholder Engagement**
   - Involve clinicians in design from day 1
   - Regular demos and feedback sessions
   - Champions program: identify early adopters

2. **Ease of Use**
   - Create simple web interface (avoid command line)
   - One-click upload and analysis
   - Email notifications when results ready

3. **Education & Training**
   - Hands-on workshops for users
   - Video tutorials and documentation
   - Office hours for troubleshooting

4. **Demonstrate Value Quickly**
   - Pilot with high-profile success cases
   - Publish case studies showing time savings
   - Track metrics: 40 hours â†’ 4 hours per analysis

**Risk Owner:** Product Manager + Clinical Champions

**Timeline:** User engagement throughout pilot phase

---

## Risk Mitigation Timeline

### **Pre-Deployment (Weeks 1-4)**
- âœ… R1: Complete HIPAA security assessment
- âœ… R3: Production readiness checklist for mcp-multiomics & mcp-fgbio
- âœ… R7: Establish clinical review process

### **Pilot Phase (Weeks 5-8)**
- âœ… R2: Process 5-10 patients with detailed cost tracking
- âœ… R5: Test with real data from 3+ institutions
- âœ… R6: Baseline infrastructure capacity testing

### **Early Production (Weeks 9-16)**
- âœ… R4: Implement API retry logic and caching
- âœ… R6: Optimize resource usage based on pilot learnings
- âœ… R9: User training and onboarding

### **Ongoing**
- âœ… R2: Monthly cost reviews and optimization
- âœ… R4: API health monitoring and alerting
- âœ… R7: Quarterly recommendation accuracy audits
- âœ… R8: Track regulatory landscape changes

---

## Risk Acceptance Criteria

**Project can proceed to production when:**
1. âœ… R1 (Privacy): HIPAA assessment complete, BAA signed, de-identification process tested
2. âœ… R2 (Costs): Pilot confirms costs within 50% of estimates, budget approved for 100 patients
3. âœ… R3 (Mocked servers): Only production-ready servers (multiomics + fgbio) deployed, others gated
4. âœ… R7 (Clinical): Review process established, disclaimers in place, CMO sign-off

**Acceptable residual risk:**
- R4 (API failures): Accept 5% failure rate with graceful degradation
- R5 (Data quality): Accept 10% rejection rate for malformed files
- R6 (Capacity): Accept queue times up to 24 hours
- R8 (Regulatory): Accept research-use-only restriction initially
- R9 (Adoption): Accept 30% utilization in first 6 months

---

## Appendix: Risk Scoring Methodology

**Impact Scale:**
- **Critical:** Patient safety, major legal/financial consequences (>$500K)
- **High:** Significant operational disruption, financial loss ($100K-$500K)
- **Medium:** Moderate impact, workarounds available ($10K-$100K)
- **Low:** Minor inconvenience, minimal cost (<$10K)

**Likelihood Scale:**
- **High:** >50% probability without mitigation
- **Medium:** 25-50% probability
- **Low:** <25% probability

**Severity Calculation:**
- Critical Impact + High Likelihood = ðŸ”´ HIGH (9-10)
- Critical Impact + Medium Likelihood = ðŸ”´ HIGH (8-9)
- High Impact + High Likelihood = ðŸ”´ HIGH (8-9)
- High Impact + Medium Likelihood = ðŸŸ¡ MEDIUM (6-7)
- Medium Impact + High Likelihood = ðŸŸ¡ MEDIUM (6-7)
- Medium Impact + Medium Likelihood = ðŸŸ¡ MEDIUM (5-6)
- All other combinations = ðŸŸ¢ LOW (1-4)

---

**Document Owner:** Project Manager / Risk Management Lead
**Last Updated:** December 27, 2025
**Next Review:** Before pilot phase start
**Distribution:** All stakeholders, development team, leadership
